Conferences - Results from #10840

Viewing 10841-10860 of 11879 articles

EAU 2014 - Poster: A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses

EAU 2014 - Poster: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials

EAU 2014 - Poster: Impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302

EAU 2014 - Nephron sparing surgery does not decrease other-causes mortality relative to radical nephrectomy in patients with clinical T1a-T1b renal mass: Results from a large multi-institutional study - Session Highlights

EAU 2014 - A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses - Session Highlights

EAU 2014 - Effects of prior use of statins in a phase 3 study of intermittent versus continuous combined androgen deprivation - Session Highlights

EAU 2014 - Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial - Session Highlights

EAU 2014 - Long-term immunotherapy by dendritic-cells based vaccine in patients with PSA-recurrent prostate cancer - Session Highlights

EAU 2014 - Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid - Session Highlights

EAU 2014 - Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials - Session Highlights

EAU 2014 - Low dose GTx-758 decreases free testosterone to levels similar to orchiectomy in men with metastatic castration resistant prostate cancer (mCRPC) - Session Highlights

EAU 2014 - Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Session Highlights

EAU 2014 - Predicting targeted therapy tumor resistance in renal cell carcinoma patient-derived xenografts implanted into chicken embryos - Session Highlights

EAU 2014 - Overall survival benefit of partial over radical nephrectomy in patients presenting with renal cell carcinoma - Session Highlights

EAU 2014 - Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects outcome of patients with muscle-invasive tumors - Session Highlights

EAU 2014 - Occult lymph node metastases in patients with muscle invasive bladder cancer: Incidence after neoadjuvant chemotherapy and cystectomy versus cystectomy alone - Session Highlights

EAU 2014 - A randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 antigen specific cancer immunotherapy in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomy...

EAU 2014 - Survival benefit of radical prostatectomy in patients with clinically advanced prostate cancer: Estimations of the number needed to treat based on competing-risks analysis - Session Highlights

EAU 2014 - Is the striated urethral sphincter at risk by standard suture ligation of the dorsal vein complex in radical prostatectomy? An anatomical study in adult human male cadavers - Session Highlights

EAU 2014 - Early start of oral sildenafil 100mg for erectile dysfunction after robotic assisted laparoscopic radical prostatectomy: Preliminary results from randomized prospective trial - Session Highlights

538
539
540
541
542
543
544
545
546
547